Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| epithelial cell | 4 studies | 29% ± 7% | |
| astrocyte | 4 studies | 26% ± 7% | |
| non-classical monocyte | 3 studies | 23% ± 1% | |
| endothelial cell | 3 studies | 20% ± 3% | |
| glutamatergic neuron | 3 studies | 30% ± 3% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 4 studies | 22% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 3064.45 | 1445 / 1445 | 100% | 27.39 | 183 / 183 |
| ovary | 100% | 1908.22 | 180 / 180 | 100% | 16.01 | 430 / 430 |
| lung | 100% | 3315.79 | 577 / 578 | 100% | 19.99 | 1155 / 1155 |
| breast | 100% | 3174.87 | 459 / 459 | 100% | 30.64 | 1114 / 1118 |
| prostate | 100% | 1897.13 | 244 / 245 | 100% | 24.18 | 502 / 502 |
| uterus | 100% | 1976.61 | 170 / 170 | 99% | 17.02 | 456 / 459 |
| intestine | 100% | 2522.62 | 966 / 966 | 99% | 21.76 | 522 / 527 |
| stomach | 100% | 2378.03 | 359 / 359 | 99% | 21.89 | 283 / 286 |
| thymus | 100% | 1557.74 | 652 / 653 | 99% | 15.10 | 599 / 605 |
| brain | 99% | 1835.43 | 2605 / 2642 | 100% | 33.70 | 705 / 705 |
| liver | 100% | 1589.78 | 225 / 226 | 99% | 13.74 | 401 / 406 |
| bladder | 100% | 1996.52 | 21 / 21 | 98% | 16.03 | 495 / 504 |
| pancreas | 98% | 1189.81 | 323 / 328 | 99% | 19.72 | 176 / 178 |
| adrenal gland | 99% | 1253.01 | 256 / 258 | 97% | 11.23 | 222 / 230 |
| skin | 100% | 2777.93 | 1807 / 1809 | 95% | 18.13 | 449 / 472 |
| kidney | 96% | 1005.44 | 85 / 89 | 99% | 27.95 | 893 / 901 |
| adipose | 100% | 3697.50 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 2387.64 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 100% | 2930.83 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 1539.85 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 18.65 | 45 / 45 |
| peripheral blood | 98% | 3068.22 | 910 / 929 | 0% | 0 | 0 / 0 |
| heart | 97% | 2591.12 | 831 / 861 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 93% | 11.95 | 27 / 29 |
| eye | 0% | 0 | 0 / 0 | 66% | 6.28 | 53 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0016567 | Biological process | protein ubiquitination |
| GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
| GO_0140627 | Biological process | ubiquitin-dependent protein catabolic process via the C-end degron rule pathway |
| GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
| GO_0000151 | Cellular component | ubiquitin ligase complex |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005829 | Cellular component | cytosol |
| GO_0031462 | Cellular component | Cul2-RING ubiquitin ligase complex |
| GO_1990756 | Molecular function | ubiquitin-like ligase-substrate adaptor activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | FEM1C |
| Protein name | Protein fem-1 homolog C (FEM1c) (FEM1-gamma) |
| Synonyms | KIAA1785 |
| Description | FUNCTION: Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation . The C-degron recognized by the DesCEND pathway is usually a motif of less than ten residues and can be present in full-length proteins, truncated proteins or proteolytically cleaved forms . The CRL2(FEM1C) complex specifically recognizes proteins with an arginine at the C-terminus: recognizes and binds proteins ending with -Lys/Arg-Xaa-Arg and -Lys/Arg-Xaa-Xaa-Arg C-degrons, such as SIL1 or OR51B2, leading to their ubiquitination and degradation . The CRL2(FEM1C) complex mediates ubiquitination and degradation of truncated MSRB1/SEPX1 selenoproteins produced by failed UGA/Sec decoding . Promotes ubiquitination and degradation of SLBP . . |
| Accessions | ENST00000274457.5 Q96JP0 |